{"ATC Code":"N05BA21","Abbreviation":"","Aliases":["Trecalmo","Rizen","Tienor","Clotiazepamum","Distensan","Clozan","Y 6047","5-(o-Chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-2H-thieno(2,3-e)-1,4-diazepin-2-one","5-(2-Chlorophenyl)-7-ethyl-1-methyl-1,3-dihydro-2H-thieno(2,3-e)(1,4)diazepin-2-one","Y-6047"],"Biological Half-Life":"4 hours","CAS":"33671-46-4","ChEBI":"CHEBI:31425","ChEMBL":"CHEMBL1697737","ChemicalClasses":["thienodiazepine"],"Chirality":"achiral","Classes":null,"DEA no":2752,"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives; Anti-Anxiety Agents; Benzodiazepines","Drug Indication":"For the treatment of anxiety disorders.","DrugClasses":[],"EINECS":"251-627-3","EliminationHalfLife":"4 hours\u003ca href='#cite_note-4'\u003e\u003csup\u003e[4]\u003c/sup\u003e\u003c/a\u003e","Erowid Experience Reports":[],"European Community (EC) Number":"251-627-3","HMDB ID":"HMDB0015512","HeavyAtomCount":21,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives; Anti-Anxiety Agents; Benzodiazepines","IUPACName":"5-(2-chlorophenyl)-7-ethyl-1-methyl-3H-thieno[2,3-e][1,4]diazepin-2-one","InChI":"InChI=1S/C16H15ClN2OS/c1-3-10-8-12-15(11-6-4-5-7-13(11)17)18-9-14(20)19(2)16(12)21-10/h4-8H,3,9H2,1-2H3","InChIKey":"CHBRHODLKOZEPZ-UHFFFAOYSA-N","Melting Point":"105-106","MolecularFormula":"C\u003csub\u003e16\u003c/sub\u003eH\u003csub\u003e15\u003c/sub\u003eClN\u003csub\u003e2\u003c/sub\u003eOS","MolecularWeight":"318.8 g/mol","Pharmacodynamics":"Clotiazepam is a thienodiazepine possessing anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. It increases the stage 2 non-rapid eye movement sleep.","Physical Description":"Solid","PrevSalts":[],"PubChemId":2811,"Record Description":["Clotiazepam is an organic molecular entity.","Clotiazepam is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Depressants substance.","Clotiazepam is a thienodiazepine, not approved for sale in the U.S. or Canada, but has been approved in the U.K. It is a schedule IV drug in Canada.","CLOTIAZEPAM is a small molecule drug with a maximum clinical trial phase of IV and is indicated for anxiety.","Clotiazepam is only found in individuals that have used or taken this drug. It is a benzodiazepine derivative, not approved for sale in the U.S. or Canada, but has been approved in the U.K. It is a schedule IV drug in Canada.Clotiazepam acts at the benzodiazepine receptors (BZD). This agonizes the action of GABA, increasing the frequency of opening of the channel chlorinates and penetration of the ions chlorinates through the ionophore. Increase in membrane polarization decreases the probability of discharge of neurons.","Clotiazepam is an organic molecular entity."],"RefCount":5,"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Clotiazepam","Name":"Clotiazepam","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q2263999","Name":"Clotiazepam","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB01559","Name":"Clotiazepam","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/2811","Name":"Clotiazepam","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1697737","Name":"Clotiazepam","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31425","Name":"Clotiazepam","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=33671-46-4","Name":"Clotiazepam","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0015512","Name":"Clotiazepam","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D01328","Name":"Clotiazepam","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/ZCN055599V","Name":"Clotiazepam","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID0022852","Name":"Clotiazepam","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 2811, Clotiazepam. Accessed June 26, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/2811\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/2811\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Clotiazepam. UNII: ZCN055599V. Global Substance Registration System. Accessed June 26, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/ZCN055599V\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/ZCN055599V\u003c/a\u003e","Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. March 31, 2023. Accessed June 26, 2025. \u003ca href=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003ehttps://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992\u003c/a\u003e","Clotiazépam. Economique et de Santé Publique. May 20, 2015. Accessed June 26, 2025. \u003ca href=https://www.has-sante.fr/upload/docs/evamed/CT-14195_VERATRAN_PIC_REEVAL_RI_Avis2_CT14195.pdf\u003ehttps://www.has-sante.fr/upload/docs/evamed/CT-14195_VERATRAN_PIC_REEVAL_RI_Avis2_CT14195.pdf\u003c/a\u003e"],"SMILES":"CCC1=CC2=C(S1)N(C(=O)CN=C2C3=CC=CC=C3Cl)C","Scheduling":[{"gov":"Brazil","ref":["3"],"schedule":"B1 substance"},{"gov":"Canada","ref":[],"schedule":"Schedule IV substance"},{"gov":"Germany","ref":[],"schedule":"prescription only/Anlage III substance"},{"gov":"United Kingdom","ref":[],"schedule":"Class C substance"},{"act":"Controlled Substances Act (CSA)","gov":"United States","ref":[],"schedule":"Schedule I"}],"Solubility":"5.37e-03 g/L","StoreUNII":["ZCN055599V"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="95.928mm" version="1.2" viewBox="0 0 86.436 95.928" width="86.436mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="96.0" stroke="none" width="87.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="1.038" x2="8.658" y1="46.207" y2="33.009"/>
                  
            <line class="bond" id="mol1bnd2" x1="8.658" x2="23.898" y1="33.009" y2="33.009"/>
                  
            <g class="bond" id="mol1bnd3">
                        
                <line x1="23.898" x2="32.839" y1="33.009" y2="45.302"/>
                        
                <line x1="26.913" x2="33.773" y1="33.009" y2="42.44"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd4" x1="32.839" x2="47.368" y1="45.302" y2="40.629"/>
                  
            <g class="bond" id="mol1bnd5">
                        
                <line x1="47.368" x2="47.368" y1="40.629" y2="25.389"/>
                        
                <line x1="44.929" x2="44.929" y1="38.852" y2="27.166"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd6" x1="47.368" x2="35.707" y1="25.389" y2="21.638"/>
                  
            <line class="bond" id="mol1bnd7" x1="23.898" x2="30.471" y1="33.009" y2="23.972"/>
                  
            <line class="bond" id="mol1bnd8" x1="47.368" x2="56.223" y1="25.389" y2="18.274"/>
                  
            <line class="bond" id="mol1bnd9" x1="62.559" x2="74.089" y1="16.608" y2="19.293"/>
                  
            <g class="bond" id="mol1bnd10">
                        
                <line x1="72.772" x2="80.192" y1="18.986" y2="9.724"/>
                        
                <line x1="74.675" x2="82.095" y1="20.511" y2="11.248"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="80.192" x2="76.482" y1="9.724" y2="14.355"/>
                <line class="hi" stroke="#FF0D0D" x1="82.095" x2="78.38499999999999" y1="11.248" y2="15.8795"/>
            </g>
                  
            <line class="bond" id="mol1bnd11" x1="74.089" x2="80.693" y1="19.293" y2="33.009"/>
                  
            <line class="bond" id="mol1bnd12" x1="80.693" x2="75.875" y1="33.009" y2="43.013"/>
                  
            <g class="bond" id="mol1bnd13">
                        
                <line x1="59.255" x2="70.784" y1="50.179" y2="47.494"/>
                        
                <line x1="59.857" x2="70.231" y1="47.535" y2="45.119"/>
                      
                <line class="hi" stroke="#3050F8" x1="70.784" x2="65.01950000000001" y1="47.494" y2="48.8365"/>
                <line class="hi" stroke="#3050F8" x1="70.231" x2="65.044" y1="45.119" y2="46.327"/>
            </g>
                  
            <line class="bond" id="mol1bnd14" x1="47.368" x2="59.255" y1="40.629" y2="50.179"/>
                  
            <line class="bond" id="mol1bnd15" x1="59.255" x2="55.87" y1="50.179" y2="65.038"/>
                  
            <g class="bond" id="mol1bnd16">
                        
                <line x1="55.87" x2="41.263" y1="65.038" y2="69.545"/>
                        
                <line x1="55.244" x2="43.342" y1="67.783" y2="71.456"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd17" x1="41.263" x2="38.013" y1="69.545" y2="84.435"/>
                  
            <g class="bond" id="mol1bnd18">
                        
                <line x1="38.013" x2="49.149" y1="84.435" y2="94.873"/>
                        
                <line x1="40.69" x2="49.777" y1="83.602" y2="92.119"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd19" x1="49.149" x2="63.778" y1="94.873" y2="90.267"/>
                  
            <g class="bond" id="mol1bnd20">
                        
                <line x1="63.778" x2="67.028" y1="90.267" y2="75.377"/>
                        
                <line x1="61.697" x2="64.348" y1="88.366" y2="76.219"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd21" x1="55.87" x2="67.028" y1="65.038" y2="75.377"/>
                  
            <line class="bond" id="mol1bnd22" x1="67.028" x2="78.38" y1="75.377" y2="71.812"/>
                  
            <line class="bond" id="mol1bnd23" x1="58.386" x2="55.87" y1="12.023" y2=".979"/>
                  
            <path class="atom" d="M34.384 21.852q-.0 .649 -.476 1.018q-.471 .363 -1.268 .363q-.417 .0 -.768 -.065q-.346 -.06 -.578 -.173v-.589q.244 .113 .607 .202q.369 .089 .762 .089q.548 .0 .828 -.214q.28 -.214 .28 -.577q-.0 -.238 -.108 -.399q-.101 -.167 -.351 -.31q-.25 -.143 -.696 -.297q-.625 -.227 -.947 -.554q-.315 -.333 -.315 -.899q-.0 -.393 .196 -.667q.203 -.279 .554 -.428q.357 -.155 .815 -.155q.405 -.0 .739 .077q.339 .072 .613 .197l-.197 .53q-.25 -.114 -.547 -.185q-.298 -.077 -.626 -.077q-.458 -.0 -.69 .196q-.232 .197 -.232 .518q-.0 .244 .101 .411q.107 .166 .339 .297q.232 .125 .631 .28q.429 .155 .727 .34q.297 .178 .452 .434q.155 .25 .155 .637z" fill="#C6C62C" id="mol1atm7" stroke="none"/>
                  
            <path class="atom" d="M61.196 18.288h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .733v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.108 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" id="mol1atm8" stroke="none"/>
                  
            <path class="atom" d="M85.876 7.396q.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM82.013 7.396q-.0 .923 .387 1.458q.393 .53 1.22 .53q.84 .0 1.221 -.53q.387 -.535 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" fill="#FF0D0D" id="mol1atm10" stroke="none"/>
                  
            <path class="atom" d="M76.029 49.174h-.72l-2.619 -4.066h-.03q.012 .239 .03 .596q.023 .357 .023 .732v2.738h-.565v-4.899h.714l2.608 4.054h.029q-.005 -.107 -.017 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm12" stroke="none"/>
                  
            <path class="atom" d="M82.062 68.835q-.786 -.0 -1.239 .53q-.452 .523 -.452 1.446q.0 .911 .417 1.447q.422 .53 1.268 .53q.321 -.0 .607 -.054q.292 -.059 .566 -.143v.536q-.274 .101 -.566 .149q-.292 .053 -.697 .053q-.744 .0 -1.25 -.309q-.5 -.31 -.75 -.875q-.25 -.572 -.25 -1.34q.0 -.744 .268 -1.309q.274 -.566 .804 -.881q.53 -.322 1.28 -.322q.78 .0 1.351 .286l-.244 .524q-.226 -.102 -.506 -.185q-.274 -.083 -.607 -.083zM84.818 73.258h-.601v-5.215h.601v5.215z" fill="#1FF01F" id="mol1atm20" stroke="none"/>
                
            <line class="hi" id="mol1bnd6" stroke="#C6C62C" x1="35.707" x2="41.5375" y1="21.638" y2="23.5135"/>
            <line class="hi" id="mol1bnd7" stroke="#C6C62C" x1="30.471" x2="27.1845" y1="23.972" y2="28.4905"/>
            <line class="hi" id="mol1bnd8" stroke="#3050F8" x1="56.223" x2="51.795500000000004" y1="18.274" y2="21.8315"/>
            <line class="hi" id="mol1bnd9" stroke="#3050F8" x1="62.559" x2="68.324" y1="16.608" y2="17.950499999999998"/>
            <line class="hi" id="mol1bnd12" stroke="#3050F8" x1="75.875" x2="78.28399999999999" y1="43.013" y2="38.010999999999996"/>
            <line class="hi" id="mol1bnd22" stroke="#1FF01F" x1="78.38" x2="72.70400000000001" y1="71.812" y2="73.5945"/>
            <line class="hi" id="mol1bnd23" stroke="#3050F8" x1="58.386" x2="57.128" y1="12.023" y2="6.5009999999999994"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":null,"Title":"Clotiazepam","UNII":"ZCN055599V","Wikidata":"Q2263999","Wikipedia":"Clotiazepam","XLogP":3.5}